Acurx Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 1.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.48M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant e...